tbuckley/cabot-search huggingface dataset:
PTU-037 Endoscopy in the Centenarians: Is it Worth the Trouble?
Authors: S Budihal, D Budihal
Journal: Gut (2016)

<h3>Introduction</h3> Gastrointestinal Endoscopy in the very elderly is generally considered risk prone and there is a degree of reluctance to perform procedures in this age group. Centenarians are people who live to or beyond 100 years of age. According to the Office of National Statistics, in 2014 there were 14,450 centenarians living in the U.K, having risen by 72% over the last decade.<sup>1</sup>It is estimated that the number of people over the age of 100 years will approximately double by 2020.<sup>2</sup> Little is known about digestive endoscopy in the centenarians. This retrospective study aimed to explore endoscopic practice in this group of patients. <h3>Methods</h3> A retrospective study was undertaken, analysing endoscopic practice in the centenarians in a University Hospital over a period of ten years (01/01/2005 to 01/01/2015). Endoscopy reports were retrieved using the Hospital’s Endoscopy Reporting tool (Unisoft) and patients’ Date of birth and demographic details were confirmed using the Trust’s patient database. <h3>Results</h3> A total of 11 procedures (7 Gastroscopies, 3 sigmoidoscopies and 1 Colonoscopy) were undertaken in 10 patients (4 male and 6 female). Oldest patient was 119 years of age and the youngest 101 years. Mean age was 105.2 years. 7 patients were Caucasians, 2 Indian and 1 Afro Caribbean of ethnicity. 72% of the procedures were undertaken on an urgent basis. 70% of patients were inpatients and majority of the procedures were undertaken by Consultants (82%). Indications included Dysphagia (36.3%), Melena (27.2%), Rectal Bleeding (27.2%) and previous Cancer (9%). The procedural yield was high (81.8%) with endoscopic intervention undertaken in 2 cases (Duodenal ulcer bleeding which was treated with adrenaline injections and haemorrhoids which were banded). Only 2 of the procedures (18%) were undertaken under sedation (midazolam). All procedures were completed and no immediate complications were noted. <h3>Conclusion</h3> To the best of the authors’ knowledge this is the only study analysing endoscopic practice in the centenarians. While we acknowledge that sample size is small it demonstrates that endoscopic procedures can be performed safely and that the diagnostic yield is high. Majority of the patients tend to be inpatients and undergo the procedure on an urgent basis by consultants.A patients’ age should not be the sole factor when deciding suitability for endoscopic procedures, bearing in mind the increasing number of centenarians requiring this service. Larger studies are required to gain a better understanding of endoscopic suitability for patients in this age group. <h3>References</h3> 1 http://www.ons.gov.uk/ons/dcp171778_418037.pdf 2 https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/223229/Centenarians.pdf <h3>Disclosure of Interest</h3> None Declared
Conventional 7+3 Consolidation Is Equal in Long-Term Outcome to High Dose ARA-C in Case of the High Total Doses of Different Anthracyclines/Anthracenedione in Induction/Consolidation - the Interim Results of Russian Randomized Multicenter AML-10 Trial
Authors: Valeri G Savchenko, Elena N. Parovichnikova, Andrey N Sokolov, Vera V Troitskaya, Larisa A Kuzmina, Galina Klyasova, Gennadyi Galstyan, Elena O. Gribanova, Sergey K. Kravchenko, Sergey N Bondarenko, Tamara Pavlovna Zagoskina, Lyubov Gavrilova, Tatyana Konstantinova, Tatyana Kaporskaya, Olga Samoilova, Alexander Pristupa, L Anchukova, E Zinina, V Moskov, E Karyakina, Alfiya Nizamutdinova, A Klimovich, Valery Lapin, E Paramonova, Tatiana Obukhova, Sergey Kulikov
Journal: Blood (2014)
FRI0478 Does Co-Medication with Csdmards Have An Impact on The Retention of Bdmards in Psoriatic Spondyloarthritis? Data from biorx.si
Authors: Ž. Rotar, A. Hočevar, S. Praprotnik, M. Tomsic
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> In clinical practice we often extrapolate experience and evidence from patients with RA to patients with PsA. The body of evidence supporting the use of csDMARD co-medication in PsA patients treated with bDMARDs is weak. <h3>Objectives</h3> Our aim was to determine whether co-medication with csDMARDs has an impact on the retention of bDMARDs in PsA. <h3>Methods</h3> In December 2015 we extracted data of patients with PsA treated with the first bDMARD with at least one follow-up visit from the mandatory national registry BioRx.si. Appropriate descriptive statistics methods were used to describe the cohort. Where applicable appropriate post hoc tests were used to compare the baseline characteristics. We used the unadjusted Kaplan-Meier method with log rank test as the post hoc test to assess the retention of the bDMARDs depending on co-medication with csDMARDs (i.e. methotrexate or leflunomide or sulfasalazine). <h3>Results</h3> At the time of extraction 276 (44% female) patients with a median (IQR) age of 49.5 (42.0–56.6) years treated for 733 person years satisfied the inclusion criteria. Median follow-up time was 1.5 years (0.6–3.2) years. 50%/20%/18%/12% were treated with adalimumab/etanercept/golimumab/infliximab, respectively. Methotrexate/leflunomide/sulfasalazine were predominantly used as co-medication in 70%/9%/5% of patients while 16% never received csDMARD co-medication. There was no significant difference in the retention of the initial bDMARD depending on csDMARD use at the initiation of the bDMARD or when the csDMARD was used on &lt;50% of follow-up visits. However, the bDMARD retention was significantly longer when csDMARD was used on more than 80% of follow-up visits (p=0.005; Figure 1). <h3>Conclusions</h3> Regular co-medication with csDMARDs seems to improve the retention of the first line bDMARDs in PsA in daily clinical practice. <h3>Disclosure of Interest</h3> None declared
Decrease in Sensitivity of PIG-A-Mutant Cells to Natural Killer Cells Conferred by Missing of Stress-Inducible Membrane Proteins ULBPs.
Authors: Nobuyoshi Hanaoka, Tatsuya Kawaguchi, Kentaro Horikawa, Shoichi Nagakura, Sonoko Ishihara, Hiroaki Mitsuya, Hideki Nakakuma
Journal: Blood (2004)
AB0449 Coupling Anti-SM Antibody Detection and Anti-Chromatin Antibody Detection Improves The Diagnosis and Prognosis of Systemic Lupus Erythematosus
Authors: G. Carvajal Alegria, C. Capaldo, A.-M. Roguedas-Contios, C. Hanrotel-Saliou, M. Pluchon, E. Pasquier, S. Jousse-Joulin, Y. Renaudineau
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Autoantibody (Ab) detection including anti-nuclear Ab (ANA) plus anti-dsDNA/Chromatin Ab and/or anti-Sm Ab is central in the diagnosis and prognosis of systemic lupus erythematosus (SLE) and several methods can be used to detect them. <h3>Objectives</h3> Our objective was to compare diagnostic accuracy for several anti-dsDNA Ab, anti-chromatin Ab and anti-Sm Ab detection. <h3>Methods</h3> Accordingly, we compared different methods for anti-dsDNA Ab [indirect immunofluorescence using <i>Crithidia Luciliae</i> (CLIFT), anti-dsDNA by ELISA, anti-dsDNA by chemiluminescence (CLIA; IDS-ISYS, IDS) and anti-chromatin Ab (dsDNA-NCX, Euroimmun)] and anti-Sm Ab by ELISA (Immuno concept) and by CLIA (IDS-ISYS, IDS)]. The evaluation was performed in 49 SLE and 98 autoimmune disease controls including rheumatoid arthritis, scleroderma, vasculitis and Sjögren9s syndrome. <h3>Results</h3> In SLE patients, Ab sensitivity (and specificity) was 97.9% for AAN, 61.2% (92.9%) for anti-chromatin Ab, 36.7% (93 9%) for anti-dsDNA Ab by CLIA, 32.6% (95.9%) for anti-dsDNA Ab by ELISA, and 30.6% (100%) by CLIFT. For anti-Sm Ab, CLIA improved its detection (sensibility 18.4% versus 8.2% by ELISA; specificity 100% both). The best associations were found for anti-chromatin Ab and CLIFT (sensitivity 67.3% and specificity 91.8%), and for anti-chromatin and anti-Sm Abs by CLIA (sensitivity 53.1% and specificity 95.2%). Several associations were identified, including, for anti-chromatin Ab, articular [Odds ratio (OR)=28,41; p=0,002] and cardio vascular disease [OR=9,47; p=0,032], plus leucopenia [OR=13,72; p=0,049]; and for anti-Sm Ab by CLIA lupus glomerulonephritis [OR =5.0, p=0.05], and pleuropulmonary manifestations [OR =25.3; p=0.004]. <h3>Conclusions</h3> Combining anti-chromatin Ab detection by ELISA and anti-Sm Ab detection by CLIA contribute to improve the diagnosis and the prognosis of SLE. <h3>Disclosure of Interest</h3> None declared
Neonatal listeriosis in the UK 2004–2014
Authors: Shari Sapuan, Christina Kortsalioudaki, Mark Anthony, John Chang, Nicholas D. Embleton, Ruppa M. Geethanath, Jim Gray, Anne Greenough, Mithilesh K. Lal, Suzanne Luck, Santosh Pattnayak, Peter Reynolds, Allison B. Russell, Timothy Scorrer, Mark Turner, Paul T. Heath, Stefania Vergnano
Journal: Journal of Infection (2016)
Prognostic Implications of Pre-Treatment Hypodiploidy and Complex Cytogenetics in Adult Patients with Acute Lymphocytic Leukemia (ALL) Treated with Hyper-CVAD
Authors: Ghayas C. Issa, Hagop M. Kantarjian, C. Cameron Yin, Koji Sasaki, Guillermo Garcia-Manero, Courtney DiNardo, Koichi Takahashi, Farhad Ravandi, Jorge E. Cortes, Naval Daver, Tapan Kadia, Srdan Verstovsek, Sherry Pierce, Elias Jabbour
Journal: Blood (2015)
AB0117 New Identified IL-23 Receptor Gene Mutations in Ankylosing Spondylitis: Table 1.
Authors: M. Akyol, A.B. Avci, S. Ureyen, E. Terzioglu
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> The pathogenesis of ankylosing spondylitis (AS) has strongly been associated with the gene <i>HLA-B27</i>; however, AS occur only in 1%–5% of HLA-B27-positive individuals and increasing evidence suggests involvement of also non-HLA genes. Previous work has confirmed association with single nucleotide polymorphisms in interleukin-23 receptor (IL-23R). <h3>Objectives</h3> The aim of the study is to confirm the association of IL-23R gene polymorphisms with ankylosing spondylitis in Turkish population and to find out possible mutations responsible from this association. <h3>Methods</h3> We included 48 AS patients and 48 healthy unrelated individuals. Extracted DNA from patient specimens was amplified with polymerase chain reaction and sequenced. <h3>Results</h3> We identified 6 new point mutations at IL-23R gene in patients with AS (Table). 2824DelC mutation (1/41 - 2,4%) was found to be in the intronic region that probably does not have an effect on the protein. 34521GT mutation (1/36 - 3,8%) was located at the exon-intron boundary and changes the exon recognition site. This should be the reason for exon skipping. The mutation probably changes the protein structure and function of IL-23R protein. Ala228Ala (2/42 - 4,8% - p.0,0306) was a silent mutation that does not change the protein structure of the IL23R protein. Ala364Gly mutation (6/43–17% - p.0,074) missense mutation was found at 6 patients as a heterozygote. Ala364Gly mutation looks associated with AS. Leu371Phe mutation (1/43 - 2,3%) was also missense mutation and caused change on the aminoacid. As the last point, Tyr436Stop is a silent mutation that is an early stop truncating the protein 194 aminoacid earlier than the usual process. <h3>Conclusions</h3> We have determined 6 new point mutations in 11 patients included. Although two of the mutations probably do not have an effect on the protein, other four mutations cause changes in the protein structure of IL-23R protein. We consider that these mutations probably contribute to the pathogenesis of AS by effecting the functions of the protein. <h3>References</h3> Brionez TF, Reveille JD. The contribution of genes outside the major histocompatibility complex to susceptibility to ankylosing spondylitis. Curr Opin Rheumatol. 2008 Jul;20(4): 384–91. Karaderi T, Harvey D, Farrar C, et al. Association between the interleukin 23 receptor and ankylosing spondylitis is confirmed by a new UK case-control study and meta-analysis of published series. Rheumatology (Oxford). 2009 Apr;48(4):386–9. <h3>Disclosure of Interest</h3> None declared
Relationship Between vitamin D Deficiency and Bone Fragility in Sickle Cell Disease: A Cohort Study of 56 adults.
Authors: Jean-Benoît Arlet, Marie Courbebaisse, Gilles Chatellier, Dominique Eladari, Jean-Claude Souberbielle, Gerard Friedlander, Mariane De Montalembert, Dominique Prié, Jacques Pouchot, Jean-Antoine Ribeil
Journal: Blood (2012)
Improved Responses and Cures with Less Hematologic Toxicity Using Anti-CD20 Bispecific Antibody Pretargeted Radionuclides Compared to Directly Radiolabeled IgG in a NHL Model.
Authors: David M. Goldenberg, Robert M. Sharkey, Habibe Karacay, Chien-Hsing Chang, Edmund A. Rossi, William J. McBride
Journal: Blood (2007)
PTH-076 Inflammatory Bowel Disease: The Consequences of Anti-TNF Therapy in The Elderly
Authors: M Ali, C McClean, Y Zou, J Goh
Journal: Gut (2016)

<h3>Introduction</h3> Existing literature regarding the efficacy and safety of anti-tumour necrosis factor (TNF) therapy in the elderly with inflammatory bowel disease (IBD) is scare and conflicting. The aim of this study is to assess the consequences of anti-TNF therapy (infliximab and adalimumab) in elderly patients with IBD. <h3>Methods</h3> A retrospective single-centre analysis of all patients ≥50 years-old who were commenced on an anti-TNF agent for IBD between September 2013 - August 2015 was performed. Patients who received less than 2 doses were excluded. The type of anti-TNF used was recorded, and whether immunomodulators were commenced prior to anti-TNF therapy. Data on treatment efficacy, treatment failure and adverse events was collected. <h3>Results</h3> 19/44 patients were male and 25/44 were female. The majority of patients (81.8%, 36/44) had a diagnosis of Crohn’s Disease, compared with 18.2% (8/44) with Ulcerative Colitis (UC). Results were analysed within subgroups based on age. The majority of patients (24/44, 55%) were aged 50–59, with 15/44 (34%) aged 60–69 and 4/44 (9%) aged 70–79. Treatment efficacy was measured by readmission with an IBD-flare and a requirement for surgery after being treated with anti-TNF. The rate of readmission with a flare was low across all age groups; of those aged 50–59, 8.3% (2/24) were readmitted, compared with 20% (3/15) aged 60–69 and 25% (1/4) aged 70–79. The median days for readmission following anti-TNF was &gt;100 days. The number of patients who required surgery also represented a small proportion: 1 patient in age 50–59 band required anal stricture dilatation, and 2 patients in age 60–69 band required a subtotal colectomy and end ileostomy for UC. Adverse events were assessed by significant reactions to treatment, infections requiring hospitalisation, a malignancy presenting after treatment, and mortality. The incidence of these adverse events was low, and did not follow any pattern related to the age of the patient at treatment (<i>Figure 1 and 2</i>), and none of the deaths observed were directly related to IBD. 40% (6/15) of patients aged 60–69 required admission to hospital due to infection; however no patients in the age bands of 50–59 or 70+ had this outcome. The infective aetiology was diverse. The median days of presentation after starting anti-TNF was &gt;200 days. <h3>Conclusion</h3> Treatment efficacy, failure and the incidence of adverse events among older patients on anti-TNF therapy appears to be low and unrelated to increasing age. Our research suggests that anti-TNF therapy is an effective and safe treatment option for IBD patients aged over 50 who have failed previous immunomodulator therapy. <h3>Reference</h3> 1 Lobaton <i>et al</i>. Efficacy and safety of anti-TNF therapy in elderly patients with inflammatory bowel disease. <i>Aliment Pharmacol Ther</i>. 2015 Aug;<b>42</b>(4):441–51. doi:10.1111/apt.13294. Epub 2015 Jun 24. <h3>Disclosure of Interest</h3> None Declared
CPX-351 Is Effective in Newly Diagnosed Older Patients with AML and with Multiple Risk Factors
Authors: Jeffrey E Lancet, Jorge E Cortes, Tibor Kovacsovics, Donna E. Hogge, Jonathan E. Kolitz, Martin S Tallman, Antje Hoering, Michael T. Chiarella, Arthur C. Louie, Eric Feldman
Journal: Blood (2012)
Expression of PRMT5 in B-Cell Chronic Lymphocytic Leukemia and Its Significance in Disease Progression and Richter's Transformation
Authors: Dalia El-Gamal, Taylor D LaFollette, Hongshan Lai, Li Chenglong, Deepa Sampath, Amy Lehman, Lianbo Yu, John C. Byrd, Robert A. Baiocchi, Rosa Lapalombella
Journal: Blood (2014)
Analysis of CRLF2/JAK Expression and Mutation Status In Adult ALL Patients
Authors: Olga Sala Torra, Holly Gundacker, Galina Pogosov, Era Pogosova-Agadjanyan, Stephen J Forman, Margaret O'Donnell, Frederick R. Appelbaum, Cheryl L. Willman, Jerald P. Radich
Journal: Blood (2010)
Tumor-targeted micelle-forming block copolymers for overcoming of multidrug resistance
Authors: Alena Braunová, Libor Kostka, Ladislav Sivák, Lucie Cuchalová, Zuzana Hvězdová, Richard Laga, Sergey Filippov, Peter Černoch, Michal Pechar, Olga Janoušková, Milada Šírová, Tomáš Etrych
Journal: Journal of Controlled Release (2016)
Activation of AKT1 in Hematopoietic Stem Cells Causes a Myeloproliferative Disease in a Tet-Inducible Mouse Model.
Authors: Christian Brandts, Miriam Rode, Beate Lindtner, Gabriele Koehler, Steffen Koschmieder, Carsten Mueller-Tidow, Wolfgang E. Berdel, Hubert Serve
Journal: Blood (2008)
Transplant Donor KIR Genotype Influences the Rate of CMV Reactivation Following T-Replete Stem Cell Transplantation.
Authors: Mark Cook, David C. Briggs, Charles F. Craddock, Premini Mahendra, Donald Milligan, Christopher Fegan, Philip Darbyshire, Sarah Lawson, Elizabeth Boxall, Paul Moss
Journal: Blood (2004)
Визначення рівня мелатоніну у щурів різної статі та віку при виразковому ураженні шлунка
Authors: V.V. Hnatiuk, N.M. Kononenko
Journal: GASTROENTEROLOGY (2016)

Метою дослідження було визначення рівня мелатоніну в сироватці крові у щурів різної статі та віку при виразковому ураженні шлунка. Матеріали та методи. Методом спирто-преднізолонового ушкодження моделювали виразкове ураження шлунка та за допомогою імуноферментного аналізу визначали рівні мелатоніну в сироватці крові у щурів різної статі, які були розподілені на групи за віком, а саме — 3, 9, 15 та 20 міс., що відповідає віку людини 14, 29–30, 43–44, 55–56 років відповідно. Результати. Встановлено, що на тлі виразкового ураження шлунка відбувається вірогідне зниження рівня мелатоніну як у самців, так і у самок у всіх вікових групах. Відносно групи контролю у щурів-самців найбільше зниження відбулося у тварин віком 9 та 20 міс. — на 39 та 43 % відповідно (р ≤ 0,05). У самок на тлі виразкового ураження шлунка зниження рівня мелатоніну відносно групи контролю було на 21–23 % (р ≤ 0,05). Обговорення. Отримані результати свідчать, що виразкове ураження шлунка, ймовірно, призводить до пошкодження ентерохромафінних клітин слизової оболонки шлунка, що супроводжується вірогідними зниженнями рівнів мелатоніну у щурів обох статей і всіх вікових груп, та дозволяють припустити, що саме у чоловіків віком 29–30 та 55–56 років виразкове ураження призводить до значного пошкодження екстрапінеальних джерел синтезу мелатоніну та більш тяжкого перебігу виразкової хвороби з розвитком ускладнень. Висновки. Таким чином, виразкове ураження шлунка призводить до зниження рівнів мелатоніну в сироватці крові у щурів різної статі та віку. Найбільше зниження рівнів мелатоніну при експериментальній виразці шлунка відбувається у щурів-самців віком 9 та 20 міс., що відповідає віку людини 29–30 та 55–56 років.
SP0124 Systemic Predisposition To CPPD and Interaction with Osteoarthritis
Authors: A. Abhishek
Journal: Annals of the Rheumatic Diseases (2016)

Calcium pyrophosphate deposition (CPPD) is generally regarded as a local joint specific phenomenon with a few reported instances of widespread polyarticular CPPD attributed to inherited disorders, severe generalised structural arthropathy, or uncommon to rare metabolic disorders like haemochromatosis, hyperparathyroidism, hypomagnesemia and hypophosphatasia. Recent research by our group has demonstrated that chondrocalcinosis (a surrogate for CPPD) occurs due to a systemic predisposition. We have also demontrated that the association between chondrocalcinosis and osteoarthirtis is joint specific and that chondrocalcinosis at both index and distant joints modifies the radiographic phenotype of lower limb large joint osteoarthritis. For instance knee chondrocalcinosis and chondrocalcinosis at distant joints (in the absence of any knee chondrocalcinosis) associate with attrition in knees with osteoarthritis. In this lecture I will describe the pathogenesis of CPPD, review the research which demonstrates that there is a systemic predisposition to CPPD, and that its interactions with osteoarthritis are joint specific. <h3>Disclosure of Interest</h3> None declared
FRI0371 The Clinical Spectrum of Medium-Sized Vessel Vasculitis
Authors: F. Alibaz-Oner, M.J. Koster, C.S. Crowson, A. Makol, S.R. Ytterberg, E.L. Matteson, K.J. Warrington
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Polyarteritis nodosa (PAN) is a systemic necrotizing vasculitis of medium sized visceral vessels. The 2012 Chapel Hill Consensus Conference Nomenclature of vasculitides defined vasculitis affecting any size of vessel in a single organ without systemic manifestations as single organ vasculitis (SOV). However, cutaneous arteritis (CA) and Gastrointestinal (GI) vasculitis are forms of SOV having indistinguishable histopathological findings from PAN. <h3>Objectives</h3> In this study, we aimed to evaluate and compare the demographics, clinical characteristics, treatment, and outcomes of patients with systemic PAN, CA and GI vasculitis. <h3>Methods</h3> We assembled retrospective cohorts of patients with PAN, CA and GI vasculitis between 1980 and 2014. The demographics, clinical characteristics, treatment and outcomes of patients were abstracted from medical records. Birmingham Vasculitis Activity Score (BVAS), prognostic Five Factor Score (FFS) and vasculitis damage index (VDI) were calculated. <h3>Results</h3> The study included 48 patients with PAN, 41 patients with CA, and 19 patients with GI vasculitis. Only 1 patient presenting as CA evolved to systemic PAN during the disease course. Most cases of PAN were idiopathic, while only 7 patients had hepatitis B and 2 patients had hepatitis C positivity. Constitutional and musculoskeletal manifestations were the most common clinical manifestations in the PAN group and were less frequent in CA and GI vasculitis. At diagnosis, 94% of patients with PAN, 93% of patients with CA and 67% of patients with GI vasculitis were treated with glucocorticoids. Additional immune-suppressive agents were used in 67% of PAN, 37% of GI vasculitis and 32% of CA. Twenty-seven patients with PAN, 18 patients with CA and 9 patients with GI vasculitis had mean follow-up of about 6 years. The five year cumulative relapse rate was 45.2% in CA, and only 9.6% in PAN. VDI was comparable in PAN and GI vasculitis, but was lower in CA. While no deaths were observed in the CA group, survival at 10-years was 66% in the PAN and 61% in GI vasculitis group. <h3>Conclusions</h3> CA and GI vasculitis appear to be distinct diseases rather than a limited expression of systemic PAN. Progression of CA to systemic PAN is very rare. Relapse risk is very low during follow-up in PAN. Patients with CA have a higher relapse rate compared to those with systemic PAN, possibly due to lower use of immunosuppressive therapy in the former group. <h3>Disclosure of Interest</h3> None declared